SHR1459 not checked

Hengrui · TG-1701

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
9 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“TR group: The first period,the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout; The second period,the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h. RT group: The first period,the subjects will be administrated with SHR-1459 in old formulation, then conduct…”In the company’s words, NCT04395053 on ClinicalTrials.gov
Tested for
Neuromyelitis Optica Spectrum Disorders, Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma, Primary Membranous Nephropathy, B-cell Tumors, Mature B Cell Neoplasms, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Main trialPhase 2
“This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs.”In the company’s words, NCT04670770 on ClinicalTrials.gov
Other names
TG-1701 · No other intervention · BTK inhibitor

Other drugs for Neuromyelitis Optica Spectrum Disorders

All 10 drugs for Neuromyelitis Optica Spectrum Disorders

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 2Completed 15 Aug 2022 An Open Label Study of the Effects of SHR1459 in NMOSDs Patients
Phase 2Unknown Apr 2023 SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Phase 2Unknown 28 Aug 2023 Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy
Phase 1Completed 11 Jul 2020 A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers
Phase 1Completed 14 Dec 2020 Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)
Phase 1Unknown 5 Jul 2022 Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers
Phase 1Completed 2 Dec 2022 A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
Phase 1Unknown 30 Dec 2023 Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor
Phase 1Terminated 21 May 2024 Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SHR1459

Following is part of Solo: you see every change to SHR1459 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in